Add. info to newsletter ”2cureX GmbH receives contribution for the development of IndiTreat® tests in immuno-oncology”
October 3, 2018
2cureX has received a grant of EUR 1,188,000 from the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung, BMBF) to adapt the IndiTreat® to individualized immuno-oncology treatment. The project is run in collaboration with the University Medical Center Hamburg-Eppendorf (Universitätsklinikum Hamburg-Eppendorf, UKE). 2cureX is co-financing the project with
EUR 378,000. The project will run until February 2020. The grant was approved in March 2017 subject to a successfully approved on-site inspection at the company’s facilities. The on-site inspection was successfully conducted on 2018-09-27. The EUR 810,000 payments (of which 2cureX receives EUR 567,000) are provided on a quarterly basis until the end of the project in February 2020.
Sedermera Fondkommission is the Certified Adviser of 2cureX.
For more information about 2cureX:
Ole Thastrup, CEO;
Phone: +45 22 11 53 99;
2cureX has developed a test called IndiTreat® (Individual Treatment Design), which is a patented method for selecting the right drug for the right patient. IndiTreat® establishes thousands of 3D micro-tumors that are functionally similar to the patient’s tumor. From a large panel of approved cancer treatments IndiTreat® selects the best treatment for the individual patient. IndiTreat® is expected to become a standard tool in the treatment design for cancer patients.
IndiTreat® is currently being clinically validated in colorectal and ovarian cancer.
The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol “2CUREX”).